Avedro announces purchase of IROC Innocross business assets

Avedro has acquired the business assets of IROC Innocross AG, expanding Avedro’s portfolio of corneal cross-linking devices and riboflavin brands, according to a company release.

IROC Innocross was the first firm to market a cross-linking device for the treatment of keratoconus and other corneal pathologies. The company has sold its UV-X devices to more than 1,000 ophthalmologists and has the largest installed base of cross-linking devices globally, according to the release.

Avedro will continue to work with IROC Innocross suppliers MDP Solutions in Switzerland and Solnovis in Germany to guarantee product supply and development.

The company currently markets its products in 62 countries. Avedro’s established product line includes the KXL System for LASIK Xtra and accelerated cross-linking, the KXL II system and a proprietary line of single-dose pharmaceutical formulations.

The KXL system and single-dose pharmacologics are currently undergoing phase 3 clinical trials at more than 100 sites in the U.S., according to the release.